ICI Pakistan Limited

Result Preview

Alfa Adhi Securities REN # REP-004 AKSEER RESEARCH REN # REP-400R

Pakistan Research

PSX: ICI Bloomberg: ICI PA

Reuters: ICI.PSX

ICI - 4QFY21 Consolidated EPS expected at PKR 16.54

- ICI Pakistan is scheduled to hold its board meeting tomorrow to consider FY21 results, wherein the consolidated profit after tax for 4QFY21 is expected to increase 9.6x YoY to PKR 1.5bn (PKR 16.54/share). This will take FY21 profit after tax to PKR 6.1bn (PKR 66.13/share). Along with the result the company is also expected to announce final cash dividend of PKR 20/share, taking cumulative pay out to PKR 40/share for FY21.
- ICI's 4QFY21E sales are likely to increase 90% YoY to PKR 20.3bn. The exponential increase in revenue is primarily attributable to low base effect, wherein the company faced a significant decline in revenues across almost all business segments in 4QFY20 owing to economic slowdown amidst country wide lockdown.
- PSF: We expect the operating profit from the PSF segment to clock in at PKR 882mn in 4QFY21 as compared to operating loss of PKR 170mn in the same period last year. This will be on the back of an increased volumetric sales and will also negate the impact of appreciation of PKR against USD. During the quarter, PSF primary margins hovered around USD 515/ton (+4% YoY) while the PKR appreciated ~6%.
- Soda Ash: Revenue from the Soda Ash segment is expected to grow 89% YoY in 4QFY21, however, higher cost of energy (Average coal prices increase 83% YoY in 4QFY21) during the period is likely to restrict the growth in operating profit from the segment.
- Life Sciences: Operating profit from the Life Sciences' segment is likely to grow 68% YoY where an increase in operating margin (+ 3.2pps YoY) is likely to be key contributor.
- **Chemicals:** 4Q operating profit of the Chemical segment is expected to grow at exponential rate 1.7x YoY primarily owing to low base effect and expansion in operating profit margins (+4.5 pps YoY).
- We change our stance to 'HOLD' on ICI, while we revise our Dec-21 price target (PT) to PKR 884/share, indicating a downside of 2% along with a dividend yield of 4.5%.

Financial Estimates						
	4QFY20	4QFY21E	YoY	FY20	FY21E	YoY
Net Sales	10,711	20,294	89%	55,256	68,380	24%
Cost of Sales	8,864	15,658	77%	44,340	52,585	19%
Gross Profit	1,847	4,636	1.5x	10,917	15,794	45%
Distri. & Admin. Exp.	1,368	1,860	36%	5,397	6,569	22%
Other Income	49	17	-64%	163	189	16%
Other Charges	72	125	75%	730	575	-21%
Finance Cost	448	417	-7%	1,891	1,111	-41%
Profit from Associate	88	59	-33%	431	461	7%
Profit Before Tax	97	2,310	23x	3,493	8,190	1.3x
Taxation	52	709	12.6x	1,131	2,270	101%
Net Income	45	1,602	35x	2,362	5,920	1.5x
NCI	100	(74)	-174%	166	187	13%
Attributable to parent	144	1,528	9.6x	2,528	6,107	1.4x
EPS	1.56	16.54		27.37	66.13	
DPS	5.00	20.00		16.00	40.00	
C						

Source: Company Accounts, Akseer Research

Key Financial Ratios - Consolidated						
	FY18A	FY19A	FY20A	FY21F	FY22F	FY23F
EPS	35.51	27.34	27.37	66.13	63.60	74.98
EPS Growth	0%	-23%	0%	142%	-4%	18%
DPS	16.50	9.00	16.00	40.00	33.00	37.00
PER	25.3	32.8	32.8	13.6	14.1	12.0
Dividend Yield	1.8%	1.0%	1.8%	4.5%	3.7%	4.1%
EV/EBITDA	13.8	13.2	11.6	8.1	7.9	6.6
P/B	4.1	3.9	3.7	3.4	3.0	2.6
ROE	17.1%	12.2%	11.6%	24.9%	20.1%	20.7%

Source: Company Accounts, Akseer Research

Key Data **PSX** Ticker ICI Target Price (PKR) 884 Current Price (PKR) 898 Upside/(Downside) (%) -2% Dividend Yield (%) 4.5% Total Return (%) + 3% 12-month High (PKR) 945 12-month Low (PKR) 671 Outstanding Shares (mn) 92 Market Cap (PKR mn) 82.944 Year End June

Source: Company Accounts, Akseer Research

Saad Nandia saad.nandia@akseerresearch.com



Valuation Basis

Our PT for ICI Pakistan Limited (ICI) has been computed using Free cash flow to equity (FCFE) method. We have used a risk free rate of 11%, beta of 1.0 and market risk premium of 6% to arrive at cost of equity of 17%.

Investment Thesis

We have a 'HOLD' recommendation on the stock based on our revised PT of 884/share. Our price target indicates a downside of 2% along with a dividend yield of 4.5%. Our investment case is based on 1) healthy contribution from Soda Ash business, 2) contributin from company's Morinaga prject, 3) growth in Life sciences and chemical divisions and 4) improved profitability from PSF segment.

Risks

Key risks to our investment thesis include 1) Supply glut in global Soda Ash market, 2) Deterioration of PSF margins, 3) fluctutation in exchange rate, 4) Lower than expected growth in Life Sciences and Chemicals business and 5) Lower than expected profitability from Morinaga project.

Company Description

ICI is engaged in the manufacture of polyester staple fibre, POY chips, soda ash, specialty chemicals, sodium bicarbonate and polyurethanes; marketing of seeds, toll manufactured and imported pharmaceuticals and animal health products; and merchanting of general chemicals and manufacturing of master batch. The Company's registered office is situated at 5 West Wharf, Karachi.

Financial Highlights - ICI

Income Statement (PKR mn) - Consolidated						
	FY18A	FY19A	FY20A	FY21F	FY22F	FY23F
Net sales	49,992	59,382	55,256	68,380	72,905	84,014
Cost of sales	41,005	49,637	44,340	52,585	56,108	64,186
Gross Profit	8,987	9,745	10,917	15,794	16,797	19,829
SG & A	4,384	4,802	5,397	6,569	7,608	8,840
Operating Profit	4,602	4,943	5,520	9,225	9,189	10,988
Other income	156	131	163	189	194	198
Other charges	757	711	730	575	556	664
Finance cost	654	1,486	1,891	1,111	1,195	1,268
Profit from Associate	586	526	431	461	617	648
Profit before tax	3,934	3,404	3,493	8,190	8,249	9,903
Taxation	636	867	1,131	2,270	2,279	2,740
Profit after tax	3,298	2,537	2,362	5,920	5,970	7,163
NCI	(18)	(11)	166	187	(96)	(238)
Attributable to parent	3,280	2,525	2,528	6,107	5,874	6,925

Source: Company Accounts, Akseer Research

Balance sheet (PKR mn) - Consolidated						
	FY18A	FY19A	FY20A	FY21F	FY22F	FY23F
PPE	24,064	27,570	27,017	29,372	31,461	33,234
Other LT assets	1,620	1,974	1,677	1,678	2,488	3,258
Non-Current Assets	25,684	29,543	29,013	31,283	34,098	36,556
Current assets	19,328	19,898	19,372	21,921	22,567	27,330
Total Assets	45,013	49,441	48,385	53,204	56,665	63,887
Non-Current liabilities	10,272	11,316	10,542	11,443	11,573	12,251
Current liabilities	14,708	16,733	15,319	17,195	17,509	20,075
Total Liabilities	24,980	28,049	25,861	28,638	29,083	32,325
Equity	20,033	21,393	22,524	24,566	27,583	31,561
Total Equity & liabilities	45,013	49,441	48,385	53,204	56,665	63,887

Source: Company Accounts, Akseer Research

Cashflow statement (PKR mn) - Consolidated						
	FY18A	FY19A	FY20A	FY21F	FY22F	FY23F
Net Income	3,280	2,525	2,528	6,107	5,874	6,925
Non-cash Charges	2,474	2,712	2,905	2,741	2,986	3,203
Operating Cash flows	(1,654)	4,158	7,457	9,339	8,735	10,963
FCFF	(6,902)	(952)	6,065	5,132	4,610	6,990
Net borrowings	8,844	1,962	(3,264)	2,046	551	1,705
FCFE	1,394	(98)	1,522	6,374	4,295	7,778
Net change in cash	421	(1,263)	126	2,309	1,438	4,831
Closing cash	1,687	424	550	2,858	4,297	9,128

Source: Company Accounts, Akseer Research

Disclaimer

This report has been prepared and marketed jointly by Akseer Research (Pvt) Limited and Alfa Adhi Securities (Pvt) Limited, hereinafter referred jointly as "JV" and is provided for information purposes only. Under no circumstances this is to be used or considered as an offer to sell or solicitation of any offer to buy. While reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. From time to time, the JV and/or any of their officers or directors may, as permitted by applicable laws, have a position, or otherwise be interested in any transaction, in any securities directly or indirectly subject of this report. This report is provided only for the information of professionals who are expected to make their own investment decisions without undue reliance on this report. Investments in capital markets are subject to market risk and the JV accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. In particular, the report takes no account of the investment objectives, financial situation and particular needs of investors, who should seek further professional advice or rely upon their own judgment and acumen before making any investment. The views expressed in this report are those of the JV's Research Department and do not necessarily reflect those of the JV or its directors. Akseer Research and Alfa Adhi Securities as firms may have business relationships, including investment--banking relationships, with the companies referred to in this report. The JV or any of their officers, directors, principals, employees, associates, close relatives may act as a market maker in the securities of the companies mentioned in this report, may have a financial interest in the securities of these companies to an amount exceeding 1% of the value of the securities of these companies, may serve or may have served in the past as a director or officer of these companies, may have received compensation from these companies for corporate advisory services, brokerage services or underwriting services or may expect to receive or intend to seek compensation from these companies for the aforesaid services, may have managed or co-managed a public offering, take-over, buyback, delisting offer of securities or various other functions for the companies mentioned in this report.

All rights reserved by the JV. This report or any portion hereof may not be reproduced, distributed or published by any person for any purpose whatsoever. Nor can it be sent to a third party without prior consent of the JV. Action could be taken for unauthorized reproduction, distribution or publication.

Valuation Methodology

To arrive at our 12-months Price Target, the JV uses different valuation methods which include: 1). DCF methodology, 2). Relative valuation methodology, and 3). Asset-based valuation methodology.

Ratings Criteria

JV employs a three-tier ratings system to rate a stock, as mentioned below, which is based upon the level of expected return for a specific stock. The rating is based on the following with time horizon of 12-months.

Rating	Expected Total Return
Buy	Greater than or equal to +15%
Hold	Between -5% and +15%

Sell Less than or equal to -5%

Ratings are updated to account for any development impacting the economy/sector/company, changes in analysts' assumptions or a combination of these factors.

Research Dissemination Policy

The JV endeavours to make all reasonable efforts to disseminate research to all eligible clients in a timely manner through either physical or electronic distribution such as email, fax mail etc.

Analyst Certification

The research analyst, denoted by 'AC' on the cover of this report, has also been involved in the preparation of this report, and is a member of JV's Equity Research Team. The analyst certifies that (1) the views expressed in this report accurately reflect his/her personal views and (2) no part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

Contact Details

Akseer Research (Pvt) LimitedAlfa Adhi Securities (Pvt) Limited1st Floor, Shaheen Chambers, KCHS block 7 & 8, off. Shahrah-e-Faisal3rd Floor, Shaheen Chambers, A-4 Central Commercial Area,T:+92-21-34320359 -60KCH Society, Block 7 & 8, Near Virtual University, KarachiE:info@akseerresearch.comT:+92-21-38694242E:info@alfaadhi.net